

Recombinant biotinylated antigen of merozoite surface antigen 1 (BcMSA1) for *Babesia canis*

CATALOG NUMBER: RAG0020BIOT

LOT NUMBER: #

RECOMBINANT ANTIGEN: recombinant antigen BcMSA1 for *B. canis*.

DESCRIPTION: recombinant antigen formed by the fragment containing a 1 to 303 of BcMSA1 for *B. canis* and fused to a His-tag in its C-terminus.

PRESENTATION: liquid protein solution

SOURCE: *Pichia pastoris*

MOLECULAR WEIGHT: SDS-PAGE analysis determines that the protein band is between the molecular markers of 116,000 Da and 66,200 Da due to the glycosylation pattern, while relative molecular mass, calculated from amino acid sequence and without glycosylation, is 43,031.64 Da.

BATCH COMPOSITION:

COMPONENTS	COMPOSITION
BcMSA1-His	recombinant antigen with a his-tag in its C-terminus
Storage buffer	20 mM phosphate buffer pH 8 and 0.15 M NaCl

QUALITY CONTROL:

1. PROTEIN CONCENTRATION DETERMINED ESPECTROPHOTOMETRICALLY

DO₂₈₀ = 0.558
 A_{0.1%} (=1 g/l) = 0.501
 CONCENTRATION*: 1.11 mg/ml

* The measurement of the protein concentration has been performed with the theoretical extinction coefficient of the recombinant protein obtained from Gill and vonHippel, 1989. It is recommended that the users carry out their absorbance determinations to avoid equipment variabilities regarding final concentration, mainly in reproducibility analysis.

2. PURITY CONTROL IN SDS-PAGE: 15%




Figure 1. SDS-PAGE analysis (15%) of 10 µl of recombinant BcMSA1. Purity is > 95% as determined by gel electrophoresis.

3. WESTERN BLOT WITH STREPTAVIDIN TO DETECT BIOTINYLATION




Figure 3. Western blot analysis in order to detect streptavidin /biotin reaction. The incubation was performed with HRP conjugated streptavidin (1:2500)

4. ABSENCE OF PRECIPITATION AFTER A FREEZING AND THAWING CYCLE: ok

LOT SPECIFICATIONS:

- 1. CONCENTRATION:** 1.11 mg/ml
- 2. TOTAL QUANTITY PER ALIQUOT:** 1 mg
- 3. TOTAL VOLUME PER ALIQUOT:** 0.945 ml
- 4. STORAGE:** Protein is shipped with dry ice. Upon arrival, it should be aliquoted to avoid repeated freezing and thawing cycles and stored at -20°C to -80°C. In order to defrost the protein, maintain the aliquot at 25°C without shaking to avoid aggregation.
- 5. TESTED APPLICATIONS:** none.
- 6. POSSIBLE APPLICATIONS:** WB, DB, Capture ELISA, nanoparticles binding, plate orientation. Where this product has not been tested for use in a particular technique, this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates. **Due to the nonspecific interaction with anti-CCDs present in normal human or animal sera, we strongly recommend using 12.5 µg of our sorbent SOR0001 on the analyzed sera in any immunoassay.**

7. OBSERVATIONS: Proteins should be maintained frozen at high concentration. The dilution to be performed for carrying out an ELISA assays, should be freshly-made with a small quantity of protein. In order to defrost the protein, maintain the aliquot at 25°C without shaking to avoid aggregation. Prior making test dilutions and after defrosting the protein, is recommended to remove possible protein aggregates by centrifuging the stock solution, avoiding alterations in the immobilization of the biomolecule to the solid surface.

RELATED PRODUCTS:

BcMSA1, Bc28.1.

BIBLIOGRAPHY:

Gill SC, von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. *Anal Biochem.* 1989 Nov 1;182(2):319-26.

Important Notes: During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 µl or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the containers cap.

Although recombinant antigens are expressed in non-pathogenic *P. pastoris* and bacterial integrity is destroyed during purification, the antigen preparation should be handled as potentially infectious.

FOR RESEARCH AND COMMERCIAL USE *IN VITRO*: not for human *in vivo* or therapeutic use.

